| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.29% | 60.56% | 61.90% | 70.72% | 28.55% | -0.62% | 56.62% | 96.26% | — | — | — | — |
| Operating Margin | 9.95% | -31.51% | -23.77% | -27.04% | -124.23% | -127.47% | -85.46% | -85.76% | -44.10% | -8889.90% | — | — |
| EBITDA Margin | 10.49% | -30.60% | -22.95% | -26.47% | -123.32% | -126.77% | -84.79% | -85.33% | -43.76% | -8870.62% | — | — |
| Net Margin | -2.26% | -43.33% | -26.68% | -31.63% | -132.43% | -129.85% | -83.48% | -69.12% | -42.44% | -8843.45% | — | — |
| Current Ratio | 1.55 | 1.41 | 1.18 | 1.48 | 1.06 | 1.98 | 1.49 | 1.76 | 2.48 | 2.59 | 11.88 | 16.05 |
| Quick Ratio | 1.46 | 1.21 | 1.03 | 1.31 | 0.91 | 1.66 | 0.93 | 1.33 | 2.48 | 2.59 | 11.88 | 16.05 |
| Debt / Equity | 1.48 | -0.79 | -1.13 | 7.07 | 1.28 | 0.39 | 0.19 | 0.02 | — | — | — | — |
| ROE | -16.39% | 141.12% | 169.78% | -990.82% | -369.94% | -154.86% | -70.84% | -22.58% | -64.45% | -199.28% | -46.35% | -35.58% |
| ROA | -1.42% | -31.45% | -21.48% | -26.31% | -53.82% | -59.53% | -36.26% | -14.41% | -21.12% | -45.22% | -42.48% | -33.37% |
| Asset Turnover | 0.63 | 0.73 | 0.81 | 0.83 | 0.41 | 0.46 | 0.43 | 0.21 | 0.50 | 0.01 | 0.00 | 0.00 |
| Book Value / Share | 0.13 | -0.23 | -0.16 | 0.05 | 0.46 | 1.79 | 3.33 | 10.96 | 2.74 | 1.81 | 4.95 | 6.76 |
Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease. Its lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia due to chronic kidney disease in adults on dialysis. The company also maintains a pipeline targeting rare kidney diseases, including praliciguat, an sGC stimulator in Phase 2 for biopsy-confirmed focal segmental glomerulosclerosis, and AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor planned for Phase 2 basket studies across complement-mediated conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional candidates like AKB-9090 address acute kidney injury associated with cardiac surgery. Akebia Therapeutics Inc. supports its portfolio through licensing agreements, such as for Vafseo in Europe, and engages in post-marketing studies to expand clinical understanding and patient access in the dialysis community. Headquartered in Cambridge, Massachusetts, the company plays a key role in addressing unmet needs in the nephrology sector with innovative oral therapies and targeted pipeline advancements.